Approved HIV Drugs
Approved HIV Drugs
IDWeek 2012: Simplified Protease Inhibitor Monotherapy Fails to Maintain HIV Suppression
- Details
- Category: HIV Treatment
- Published on Friday, 26 October 2012 00:00
- Written by Liz Highleyman
A simplified regimen of lopinavir/ritonavir (Kaletra) monotherapy did not keep HIV viral load fully suppressed after patients switched from a standard 3-drug antiretroviral regimen, researchers reported at the IDWeek 2012 conference last week in San Diego.
ICAAC 2012: Atazanavir Linked to Kidney Stones in People with HIV
- Details
- Category: HIV Treatment
- Published on Tuesday, 23 October 2012 00:00
- Written by Liz Highleyman
HIV positive people taking ritonavir-boosted atazanavir (Reyataz) are more likely to develop kidney stones than those using other antiretroviral medications, according to study data presented at the recent 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2012) in San Francisco and published in the November 1, 2012 issue of Clinical Infectious Diseases. Another study suggested that darunavir (Prezista) may also raise the risk.
ICAAC 2012: Simplified Abacavir/Atazanavir Combo Keeps HIV Suppressed, May Help Bones
- Details
- Category: Approved HIV Drugs
- Published on Wednesday, 10 October 2012 00:00
- Written by Liz Highleyman
Substituting abacavir/lamivudine (the drugs in Epzicom) for tenofovir/emtricitabine (the drugs in Truvada) and dropping the ritonavir (Norvir) booster with atazanavir (Reyataz) maintains undetectable HIV viral load and improves biomarkers of bone loss, researchers reported at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2012) last month in San Francisco. 
1 in 5 People on Atripla Switch, Usually Due to Central Nervous System Side Effects
- Details
- Category: Approved HIV Drugs
- Published on Tuesday, 16 October 2012 00:00
- Written by Liz Highleyman
One-fifth of all people who start the Atripla (efavirenz/tenofovir/emtricitabine) combination pill eventually may need to change to a different regimen, most often due to neuropsychiatric symptoms such as insomnia, abnormal dreams, dizziness, anxiety, or depression, according to a study described in the July 17, 2012, issue of AIDS. 
DHHS Panel Adds Stribild Quad Pill As Alternative Regimen for Treatment-naive HIV Patients
- Details
- Category: Approved HIV Drugs
- Published on Thursday, 20 September 2012 00:00
- Written by Liz Highleyman
The U.S. Department of Health and Human Services (DHHS) Panel on Antiretroviral Guidelines for Adults and Adolescents issued a statement this week indicating that the newly approved Stribild (elvitegravir/cobicistat/tenofovir/emtricitabine) single-tablet regimen has been included as an alternative regimen option for people starting HIV treatment for the first time. 
More Articles...
- FDA Review Finds No Link Between Abacavir Use and Heart Attacks
- ICAAC 2012: Stribild Quad Pill Has Potent Anti-HIV Activity with Fewer Side Effects
- AIDS 2012: Raltegravir Remains Effective and Well-tolerated at 5 Years
- AIDS 2012: Switching from Protease Inhibitor to Complera Maintains Viral Suppression, Lowers Lipids
Web Design and Development by